
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
University Department of Medicine, Queen Mary Hospital [E. C. C., K. W. T., B. L., J. C. M. H., W. K. L., Y. L. K.]; Department of Pathology, Kowloon Hospital [S. Y. L.]; and Department of Pathology, Tseung Kwan O Hospital [K. H. F.], Hong Kong
This study was aimed at defining patterns of aberrant gene methylation in non-small cell lung cancer (NSCLC) in Chinese patients and its use in detecting cancer cells in bronchoalveolar lavage (BAL).
The methylation-specific PCR (MSP) was used to study methylation of the p16, retinoic acid receptor-ß (RARß), death-associated protein (DAP) kinase, and O6-methylguanine-DNA-methyltransferase (MGMT) genes in 75 NSCLCs [44 adenocarcinomas and 31 squamous cell carcinomas (SCCs)] and 68 BALs from suspected lung cancers.
More females had adenocarcinoma than SCC (11 of 44 versus 2 of 31, P = 0.04). Aberrant methylation in at least one gene was found in 63 of 75 (84%) NSCLCs. p16, RARß, DAP kinase, and MGMT methylation was similar in adenocarcinoma and SCC. However, females with NSCLC showed more frequent p16 methylation than males (12 of 13 versus 36 of 62, P = 0.02), because of more frequent p16 methylation in female adenocarcinomas (10 of 11 versus 17 of 33, P = 0.02). This sexual difference was not observed in RARß, DAP kinase, and MGMT. At 92%, the frequency of p16 methylation in Chinese female NSCLC is one of the highest known. For BAL, MSP and cytological analysis showed concordant and discordant results in 25 of 68 and 43 of 68 samples. Of 41 MSP+/cytology- cases, 35 were eventually shown to have malignant lung lesions, 4 were at high risk but had no evidence of lung cancer, and 2 were lost to follow-up. There were two MSP-/cytology+ cases.
Frequent gene methylations were seen in Chinese NSCLC patients. More frequent p16 methylation was seen in female patients. MSP is a useful molecular adjunct for cancer cell detection in BAL samples.
This article has been cited by other articles:
![]() |
C S Chim, W W L Chan, and Y L Kwong Epigenetic dysregulation of the DAP kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in acute leukaemias J. Clin. Pathol., July 1, 2008; 61(7): 844 - 847. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-S. Chim, R. Liang, T.-K. Fung, C.-L. Choi, and Y.-L. Kwong Epigenetic dysregulation of the death-associated protein kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma J. Clin. Pathol., June 1, 2007; 60(6): 664 - 669. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Schmiemann, A. Bocking, M. Kazimirek, A. S. C. Onofre, H. E. Gabbert, R. Kappes, C. D. Gerharz, and H. J. Grote Methylation Assay for the Diagnosis of Lung Cancer on Bronchial Aspirates: A Cohort Study Clin. Cancer Res., November 1, 2005; 11(21): 7728 - 7734. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Miyamoto and T. Ushijima Diagnostic and Therapeutic Applications of Epigenetics Jpn. J. Clin. Oncol., June 1, 2005; 35(6): 293 - 301. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Topaloglu, M. O. Hoque, Y. Tokumaru, J. Lee, E. Ratovitski, D. Sidransky, and C.-s. Moon Detection of Promoter Hypermethylation of Multiple Genes in the Tumor and Bronchoalveolar Lavage of Patients with Lung Cancer Clin. Cancer Res., April 1, 2004; 10(7): 2284 - 2288. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. N. Reddy, W. W. Jiang, M. Kim, N. Benoit, R. Taylor, J. Clinger, D. Sidransky, and J. A. Califano Death-Associated Protein Kinase Promoter Hypermethylation in Normal Human Lymphocytes Cancer Res., November 15, 2003; 63(22): 7694 - 7698. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |